Oragenics, Inc. (OGEN) Financial Ratios
23 years of historical data (2003–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.00
↓-100% vs avg
5yr avg: 51.55
30Y Low0.0·High153.2
ROE
↓
-237.7%
↓+12% vs avg
5yr avg: -270.6%
30Y Low-448%·High-44%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
OGEN Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Oragenics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $3M | $2M | $73M | $380M | $380M | $1.5B | $761M | $663M | $336M | $347M | $723M |
| Enterprise Value | $-4169759553 | $-4170695481 | $73M | $377M | $369M | $1.5B | $745M | $646M | $316M | $341M | $719M |
| P/E Ratio → | -0.13 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.00 | 0.00 | — | 119.95 | 29.21 | 57.04 | 45.21 | 38.50 | 16.09 | 54.96 | 243.67 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
OGEN EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
OGEN Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -237.7% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -237.7% | -237.7% | -714.9% | -255.4% | -72.4% | -72.5% | -155.1% | -81.7% | -72.9% | -145.0% | -182.2% |
| ROA | -195.5% | -195.5% | -328.3% | -209.4% | -66.5% | -67.0% | -137.5% | -74.5% | -67.8% | -116.8% | -139.0% |
| ROIC | -0.3% | -0.3% | — | -1416.2% | -972.3% | -19448.1% | -84585.0% | -3213.3% | -1457.5% | -2184.6% | — |
| ROCE | -0.2% | -0.2% | -714.3% | -256.0% | -72.2% | -71.5% | -151.2% | -81.9% | -73.5% | -144.8% | -222.0% |
OGEN Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $4.4B exceeds total debt of $227M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | — | 0.10 | 0.05 | 0.03 | 0.05 | 0.06 | 0.01 | 0.01 | 0.02 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.50 | — | -1.00 | -0.83 | -1.00 | -0.99 | -1.00 | -0.96 | -0.96 | -1.35 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -11.91 | -11.91 | -353.99 | — | -954.83 | -1000.95 | -2493.35 | -2175.07 | -1727.27 | -31.06 | -2075.44 |
Net cash position: cash ($4.4B) exceeds total debt ($227M)
OGEN Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Oragenics, Inc.'s current ratio of 44.28x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 2.15x to 44.28x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 44.28 | 44.28 | 0.87 | 2.15 | 8.95 | 19.17 | 13.40 | 10.18 | 18.79 | 8.01 | 3.14 |
| Quick Ratio | 44.28 | 44.28 | 0.87 | 2.15 | 8.95 | 19.17 | 13.40 | 10.18 | 18.79 | 8.01 | 3.14 |
| Cash Ratio | 36.95 | 36.95 | 0.51 | 1.94 | 7.16 | 18.87 | 13.14 | 9.87 | 17.31 | 6.86 | 3.04 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
OGEN Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Oragenics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | 0.1% | — | — | 0.0% | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $2M | $7M | $2M | $2M | $2M | $942187 | $704732 | $217318 | $82104 | $74348 |
Peer Comparison
Compare OGEN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 OGENYou | $3M | -0.1 | — | — | — | — | -237.7% | -0.3% | — |
 SIGA | $339M | 14.3 | 7.6 | 7.0 | 68.6% | 25.1% | 11.2% | 33.7% | 0.0 |
 ADMA | $2B | 14.1 | 10.1 | 73.1 | 57.4% | 37.5% | 35.6% | 36.0% | 0.4 |
 NVAX | $2B | 3.6 | 2.6 | — | 93.7% | 50.1% | — | — | 0.4 |
 DYAI | $27M | -3.7 | — | — | 65.8% | -168.8% | -139.2% | -1669.3% | — |
 VXRT | $178M | 10.6 | 7.4 | 23.5 | — | 7.6% | 22.3% | 27.1% | 0.5 |
 PRPH | $5M | -0.0 | — | — | -2.2% | -570.6% | -188.1% | -59.4% | — |
 HALO | $8B | 25.5 | 8.3 | 11.9 | 78.1% | 58.4% | 153.6% | 73.4% | — |
 ORMP | $160M | -8.3 | — | — | — | — | -12.4% | -6.5% | — |
 CRL | $9B | -62.5 | 13.0 | 17.3 | 30.5% | 12.6% | -4.3% | 6.3% | 3.4 |
 ICLR | $10B | 13.1 | 7.9 | 8.5 | 29.4% | 13.3% | 8.4% | 6.5% | 2.3 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 23 years · Updated daily
See OGEN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs OGEN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare OGEN vs SIGA
Side-by-side business, growth, and profitability comparison vs SIGA Technologies, Inc..
Start ComparisonOGEN — Frequently Asked Questions
Quick answers to the most common questions about buying OGEN stock.
What is Oragenics, Inc.'s P/E ratio?
Oragenics, Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
What is Oragenics, Inc.'s ROE?
Oragenics, Inc.'s return on equity (ROE) is -237.7%. The historical average is -150.4%.
Is OGEN stock overvalued?
Based on historical data, Oragenics, Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.